




RealRate

PHARMACEUTICAL 2022

Ayala Pharmaceuticals Inc
Rank 170 of 471

ADVAXIS
IMMUNOTHERAPIES™



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Ayala Pharmaceuticals Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 10% points.

The company's Economic Capital Ratio, given in the ranking table, is 332%, being 57% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	43,257
Cost of Goods Sold	0
Intangible Assets	3,354
Liabilities, Current	7,880
Liabilities, Non-Current	12
Other Assets	51
Other Compr. Net Income	0
Other Expenses	51
Other Liabilities	0
Other Net Income	975
Other Revenues	3,240
Property and Equipment	118
Research and Development	10,562
Selling, General and Administrative Expense	11,464

Output Variable	Value in 1000 USD
Assets	46,780
Liabilities	7,892
Expenses	22,077
Revenues	3,240
Stockholders Equity	38,888
Net Income	-17,862
Comprehensive Net Income	-17,862
BaseVar	40,482
ECR before Limited Liability	245%
Economic Capital Ratio	332%